IGF1R and intrahepatic cholangiocarcinoma: Because most cells displayed elevated expression of Fgfr, Vegfr, and Igfr, multiple TKIs such as sorafenib, regorafenib, and lenvatinib, which are approved for treating HCC, could also be used for ICC therapy.